MyJournals Home  

RSS FeedsPharmaceuticals, Vol. 12, Pages 62: Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase (Pharmaceuticals)


20 april 2019 08:01:40

Pharmaceuticals, Vol. 12, Pages 62: Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase (Pharmaceuticals)

One of the major factors contributing to HIV-1 drug resistance is suboptimal adherence to combination antiretroviral therapy (cART). Currently, recommended cART for HIV-1 treatment is a three-drug combination, whereas the pre-exposure prophylaxis (PrEP) regimens consist of one or two antivirals. Treatment regimens require adherence to a once or twice (in a subset of patients) daily dose. Long-acting formulations such as injections administered monthly could improve adherence and convenience, and thereby have potential to enhance the chances of expected outcomes, although long-lasting drug concentrations can also contribute to clinical issues like adverse events and development of drug resistance. Globally, two long-acting antivirals have been approved, and fifteen are in clinical trials. More than half of investigational long-acting antivirals target HIV-1 reverse transcriptase (HIV-1 RT) and/or integrase (HIV-1 IN). Here, we discuss the status and potential of long-acting inhibitors, including rilpivirine (RPV), dapivirine (DPV), and 4-ethynyl-2-fluoro-2-deoxyadenosine (EFdA; also known as MK-8591), which target RT, and cabotegravir (CAB), which targets IN. The outcomes of various clinical trials appear quite satisfactory, and the future of long-acting HIV-1 regimens appears bright. Digg Facebook Google StumbleUpon Twitter
55 viewsCategory: Medicine, Pharmacology
Pharmaceuticals, Vol. 12, Pages 61: Hierarchical Virtual Screening of Potential Insectides Inhibitors of Acetylcholinesterase and Juvenile Hormone from Temephos (Pharmaceuticals)
Pharmaceuticals, Vol. 12, Pages 63: Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines (Pharmaceuticals)
blog comments powered by Disqus
The latest issues of all your favorite science journals on one page


Register | Retrieve



Use these buttons to bookmark us: Digg Facebook Google StumbleUpon Twitter

Valid HTML 4.01 Transitional
Copyright © 2008 - 2019 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn